NPPA Revises Ceiling Price of Anti-Rabies Immunoglobulin Injection

Susmita Roy

NPPA Revises Ceiling Price of Anti-Rabies Immunoglobulin Injection

Written By : Susmita Roy Published On 2026-07-12T15:00:17+05:30 | Updated On 12 July 2026 3:00 PM IST

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of Anti-rabies Immunoglobulin Injection 300 IU/ml under the provisions of the Drugs (Prices Control) Order (DPCO), 2013, following a review order issued by the Department of Pharmaceuticals (DoP).

As per the latest notification, the ceiling price of Anti-rabies Immunoglobulin Injection 300 IU/ml has been revised from Rs. 112.19 per ml to Rs. 119.48 per ml. The revised ceiling price includes the Wholesale Price Index (WPI) impact of 0.64956% for the year 2026 and is exclusive of applicable Goods and Services Tax (GST).

The revised price has been notified in implementation of the Department of Pharmaceuticals Review Order No. 31015/02/2025-Pricing dated March 27, 2026, issued under Paragraph 31 of the Drugs (Prices Control) Order, 2013. The notification supersedes the earlier NPPA notification S.O. 1575(E) dated March 25, 2026 relating to the same scheduled formulation.

Also Read: NPPA Fixes Retail Prices for 39 New Drug Formulations Including Tenecteplase at Rs 60,238

The notice stated that in implementation of directions of review order issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date specified in the Column (8) of the table, the National Pharmaceutical Pricing Authority, has fixed/revised the price including WPI impact @0.64956% for the year 2026 as specified in column (6) of the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Sl. No.	Medicine	Dosage Form & Strength	Unit	Ceiling Price under NLEM, 2022 (Rs.)	Revised Ceiling Price based on Review Order & WPI @0.64956% (Rs.)	Review Order	Existing SO number and date
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1	Anti-rabies Immunoglobulin	Injection 300 IU/ml	1 ml	112.19	119.48	31015/02/2025-Pricing dated 27.03.2026	S.O. 1575(E) dated 25.03.2026 (Sl. No. 58)

The notice further added:

(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (6) in the above table plus Goods and Services Tax as applicable, if any.

(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (6) in the above table plus Goods and Services Tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in FormIV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

Also Read: NPPA Hikes Ceiling Prices of BCG, Measles and MR Vaccines

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/2026/07/10/274326-359023.pdf

national pharmaceutical pricing authoritynppaceiling priceantirabies vaccineantirabies immunoglubulin injectiondrug price control orderDepartment of Pharmaceuticals

Susmita Roy

Mpharm (Pharmacology)

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.